Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management.
Publication
, Journal Article
Marcus, C; Butler, P; Bagrodia, A; Cole, S; Subramaniam, RM
Published in: AJR Am J Roentgenol
August 2020
OBJECTIVE. The purpose of this article is to review the utility of 18F-fluciclovine PET/CT in the evaluation of recurrent prostate cancer. CONCLUSION. Fluorine-18-labeled fluciclovine PET/CT has shown promise in the evaluation of recurrent prostate cancer. Its performance has been superior to that of other imaging modalities. It has had good diagnostic accuracy, especially in the detection of extra-prostatic disease recurrence, and the findings have an impact on treatment planning. Gallium-68-labeled prostate-specific membrane antigen PET/CT has also had excellent performance in the detection of biochemically recurrent prostate cancer with detection rates superior to those of fluciclovine PET/CT.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
AJR Am J Roentgenol
DOI
EISSN
1546-3141
Publication Date
August 2020
Volume
215
Issue
2
Start / End Page
267 / 276
Location
United States
Related Subject Headings
- Prostatic Neoplasms
- Prostate-Specific Antigen
- Positron Emission Tomography Computed Tomography
- Nuclear Medicine & Medical Imaging
- Neoplasm Recurrence, Local
- Male
- Humans
- Cyclobutanes
- Carboxylic Acids
- 3202 Clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Marcus, C., Butler, P., Bagrodia, A., Cole, S., & Subramaniam, R. M. (2020). Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management. AJR Am J Roentgenol, 215(2), 267–276. https://doi.org/10.2214/AJR.19.22404
Marcus, Charles, Peter Butler, Aditya Bagrodia, Suzanne Cole, and Rathan M. Subramaniam. “Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management.” AJR Am J Roentgenol 215, no. 2 (August 2020): 267–76. https://doi.org/10.2214/AJR.19.22404.
Marcus C, Butler P, Bagrodia A, Cole S, Subramaniam RM. Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management. AJR Am J Roentgenol. 2020 Aug;215(2):267–76.
Marcus, Charles, et al. “Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management.” AJR Am J Roentgenol, vol. 215, no. 2, Aug. 2020, pp. 267–76. Pubmed, doi:10.2214/AJR.19.22404.
Marcus C, Butler P, Bagrodia A, Cole S, Subramaniam RM. Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management. AJR Am J Roentgenol. 2020 Aug;215(2):267–276.
Published In
AJR Am J Roentgenol
DOI
EISSN
1546-3141
Publication Date
August 2020
Volume
215
Issue
2
Start / End Page
267 / 276
Location
United States
Related Subject Headings
- Prostatic Neoplasms
- Prostate-Specific Antigen
- Positron Emission Tomography Computed Tomography
- Nuclear Medicine & Medical Imaging
- Neoplasm Recurrence, Local
- Male
- Humans
- Cyclobutanes
- Carboxylic Acids
- 3202 Clinical sciences